| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 43 | 2021 | 7551 | 1.440 |
Why?
|
| Ovarian Neoplasms | 21 | 2021 | 4638 | 1.210 |
Why?
|
| Positron-Emission Tomography | 15 | 2020 | 2173 | 1.140 |
Why?
|
| Uterine Cervical Neoplasms | 19 | 2022 | 1833 | 1.110 |
Why?
|
| Fluorodeoxyglucose F18 | 10 | 2020 | 1226 | 1.060 |
Why?
|
| Colonography, Computed Tomographic | 8 | 2014 | 53 | 0.940 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2020 | 7702 | 0.900 |
Why?
|
| Cervix Uteri | 4 | 2016 | 253 | 0.880 |
Why?
|
| Peritoneal Neoplasms | 9 | 2020 | 821 | 0.860 |
Why?
|
| Genital Neoplasms, Female | 6 | 2020 | 735 | 0.850 |
Why?
|
| Endometrial Neoplasms | 9 | 2020 | 1341 | 0.790 |
Why?
|
| Subtraction Technique | 3 | 2010 | 141 | 0.760 |
Why?
|
| CA-125 Antigen | 4 | 2020 | 226 | 0.630 |
Why?
|
| Radiation Injuries | 8 | 2011 | 1411 | 0.590 |
Why?
|
| Diagnostic Imaging | 4 | 2010 | 1162 | 0.590 |
Why?
|
| Hernia, Diaphragmatic | 2 | 2013 | 121 | 0.550 |
Why?
|
| Radiotherapy | 7 | 2011 | 1824 | 0.540 |
Why?
|
| Abdominal Neoplasms | 3 | 2006 | 231 | 0.510 |
Why?
|
| Colorectal Neoplasms | 8 | 2012 | 3578 | 0.490 |
Why?
|
| Rectal Neoplasms | 4 | 2011 | 1202 | 0.480 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2009 | 489 | 0.480 |
Why?
|
| Thoracic Neoplasms | 2 | 2006 | 337 | 0.450 |
Why?
|
| Endometrium | 3 | 2016 | 470 | 0.440 |
Why?
|
| Calcinosis | 1 | 2016 | 423 | 0.440 |
Why?
|
| Sensitivity and Specificity | 21 | 2017 | 4971 | 0.440 |
Why?
|
| Esophageal Neoplasms | 5 | 2013 | 3168 | 0.440 |
Why?
|
| Pelvic Neoplasms | 2 | 2006 | 189 | 0.440 |
Why?
|
| Fallopian Tube Neoplasms | 5 | 2014 | 153 | 0.430 |
Why?
|
| Neoplasm Staging | 26 | 2020 | 13658 | 0.410 |
Why?
|
| Esophagectomy | 2 | 2013 | 911 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2020 | 10035 | 0.390 |
Why?
|
| Contrast Media | 9 | 2018 | 1472 | 0.390 |
Why?
|
| Female | 81 | 2022 | 141928 | 0.390 |
Why?
|
| Mullerian Ducts | 1 | 2011 | 76 | 0.390 |
Why?
|
| Colonic Polyps | 6 | 2014 | 209 | 0.380 |
Why?
|
| Radiopharmaceuticals | 8 | 2013 | 1301 | 0.380 |
Why?
|
| Middle Aged | 58 | 2022 | 86204 | 0.360 |
Why?
|
| Adenocarcinoma | 11 | 2013 | 7789 | 0.360 |
Why?
|
| Tomography, Emission-Computed | 3 | 2007 | 310 | 0.350 |
Why?
|
| Aged | 49 | 2022 | 70117 | 0.350 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2020 | 833 | 0.350 |
Why?
|
| Humans | 97 | 2022 | 261506 | 0.330 |
Why?
|
| Adenoma | 5 | 2014 | 716 | 0.320 |
Why?
|
| Adipose Tissue, Brown | 1 | 2009 | 112 | 0.320 |
Why?
|
| Cystadenoma | 1 | 2007 | 26 | 0.320 |
Why?
|
| Adult | 45 | 2022 | 77950 | 0.290 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2020 | 486 | 0.280 |
Why?
|
| Pheochromocytoma | 1 | 2009 | 281 | 0.270 |
Why?
|
| Radiographic Image Enhancement | 3 | 2018 | 402 | 0.270 |
Why?
|
| BRCA2 Protein | 1 | 2007 | 358 | 0.270 |
Why?
|
| Pelvic Bones | 2 | 2020 | 95 | 0.260 |
Why?
|
| Microsatellite Instability | 2 | 2018 | 400 | 0.260 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 4744 | 0.260 |
Why?
|
| Aged, 80 and over | 22 | 2022 | 29902 | 0.250 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2006 | 600 | 0.230 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2016 | 341 | 0.230 |
Why?
|
| Tuberculosis | 1 | 2010 | 548 | 0.230 |
Why?
|
| Fractures, Bone | 2 | 2020 | 291 | 0.220 |
Why?
|
| Liver Diseases | 1 | 2007 | 574 | 0.210 |
Why?
|
| Neoplasms, Second Primary | 2 | 2007 | 1350 | 0.210 |
Why?
|
| Bone Density | 3 | 2022 | 476 | 0.210 |
Why?
|
| Pelvis | 2 | 2014 | 362 | 0.200 |
Why?
|
| Neoplasm, Residual | 4 | 2017 | 1656 | 0.200 |
Why?
|
| Urogenital System | 1 | 2001 | 59 | 0.200 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2006 | 502 | 0.200 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2021 | 35 | 0.200 |
Why?
|
| Image Enhancement | 3 | 2013 | 561 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 15862 | 0.190 |
Why?
|
| Reproducibility of Results | 9 | 2017 | 6009 | 0.190 |
Why?
|
| Urogenital Neoplasms | 1 | 2001 | 108 | 0.190 |
Why?
|
| Lymph Nodes | 4 | 2017 | 2967 | 0.190 |
Why?
|
| Radiography, Thoracic | 2 | 2010 | 462 | 0.190 |
Why?
|
| Liver Neoplasms | 4 | 2011 | 4557 | 0.190 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 133 | 0.180 |
Why?
|
| Follow-Up Studies | 10 | 2013 | 14889 | 0.180 |
Why?
|
| Brachial Plexus | 2 | 1998 | 45 | 0.180 |
Why?
|
| Lymphatic Metastasis | 9 | 2013 | 4844 | 0.180 |
Why?
|
| Carcinoma | 3 | 2011 | 2578 | 0.170 |
Why?
|
| Esophageal Diseases | 1 | 2019 | 69 | 0.170 |
Why?
|
| Teratoma | 1 | 2021 | 236 | 0.170 |
Why?
|
| Lymphography | 3 | 2003 | 51 | 0.160 |
Why?
|
| Radiotherapy, Conformal | 4 | 2013 | 902 | 0.160 |
Why?
|
| Prospective Studies | 12 | 2022 | 12873 | 0.160 |
Why?
|
| Retrospective Studies | 16 | 2018 | 37905 | 0.160 |
Why?
|
| Postoperative Complications | 1 | 2013 | 5542 | 0.160 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 328 | 0.160 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 10331 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2016 | 592 | 0.160 |
Why?
|
| Parathyroid Neoplasms | 1 | 1999 | 185 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 3981 | 0.150 |
Why?
|
| Mediastinal Neoplasms | 2 | 2011 | 423 | 0.150 |
Why?
|
| Gadolinium DTPA | 2 | 2018 | 172 | 0.150 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2017 | 54 | 0.140 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2002 | 262 | 0.140 |
Why?
|
| Cytomegalovirus | 1 | 2019 | 482 | 0.140 |
Why?
|
| Ultrasonography | 6 | 2021 | 1863 | 0.140 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2017 | 108 | 0.140 |
Why?
|
| Predictive Value of Tests | 8 | 2018 | 4892 | 0.140 |
Why?
|
| Combined Modality Therapy | 7 | 2011 | 8865 | 0.130 |
Why?
|
| Colonic Neoplasms | 3 | 2014 | 1390 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 1 | 2019 | 462 | 0.130 |
Why?
|
| Myometrium | 1 | 2015 | 79 | 0.130 |
Why?
|
| Brachytherapy | 4 | 2012 | 977 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2017 | 519 | 0.120 |
Why?
|
| Male | 26 | 2014 | 123000 | 0.120 |
Why?
|
| Observer Variation | 2 | 2013 | 671 | 0.120 |
Why?
|
| Margins of Excision | 1 | 2016 | 285 | 0.120 |
Why?
|
| Intestine, Small | 3 | 2006 | 499 | 0.120 |
Why?
|
| Intestinal Neoplasms | 2 | 2006 | 189 | 0.110 |
Why?
|
| Triiodobenzoic Acids | 1 | 2013 | 68 | 0.110 |
Why?
|
| Early Diagnosis | 2 | 2010 | 298 | 0.110 |
Why?
|
| Lymphangioma, Cystic | 1 | 1993 | 20 | 0.110 |
Why?
|
| Hysterectomy | 3 | 2013 | 611 | 0.110 |
Why?
|
| Research Design | 1 | 2010 | 1544 | 0.110 |
Why?
|
| Radiotherapy Dosage | 6 | 2007 | 3842 | 0.110 |
Why?
|
| Biopsy | 4 | 2019 | 3443 | 0.110 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2017 | 475 | 0.110 |
Why?
|
| Thymus Neoplasms | 1 | 1998 | 400 | 0.110 |
Why?
|
| Vulvar Neoplasms | 1 | 2014 | 236 | 0.110 |
Why?
|
| Clinical Competence | 2 | 2011 | 1270 | 0.110 |
Why?
|
| Fallopian Tube Diseases | 1 | 2012 | 18 | 0.110 |
Why?
|
| Cisplatin | 3 | 2011 | 2432 | 0.110 |
Why?
|
| Colonoscopy | 5 | 2011 | 518 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2018 | 32848 | 0.100 |
Why?
|
| Young Adult | 7 | 2022 | 21445 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2012 | 925 | 0.100 |
Why?
|
| Preoperative Care | 2 | 2016 | 1529 | 0.100 |
Why?
|
| Amifostine | 1 | 2011 | 97 | 0.100 |
Why?
|
| Carcinoma, Adenosquamous | 3 | 2007 | 103 | 0.100 |
Why?
|
| Smoking | 1 | 2010 | 2440 | 0.100 |
Why?
|
| Cathartics | 1 | 2011 | 42 | 0.100 |
Why?
|
| Electrolytes | 1 | 2011 | 68 | 0.100 |
Why?
|
| Radiation-Protective Agents | 1 | 2011 | 128 | 0.100 |
Why?
|
| Citric Acid | 1 | 2011 | 54 | 0.100 |
Why?
|
| Carboplatin | 2 | 2010 | 823 | 0.090 |
Why?
|
| Phosphates | 1 | 2011 | 187 | 0.090 |
Why?
|
| Organometallic Compounds | 1 | 2011 | 191 | 0.090 |
Why?
|
| Incidence | 4 | 2013 | 5673 | 0.090 |
Why?
|
| Viscera | 2 | 2006 | 81 | 0.090 |
Why?
|
| Reference Values | 2 | 2010 | 1099 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2020 | 2104 | 0.090 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2010 | 323 | 0.090 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2009 | 14 | 0.090 |
Why?
|
| Uterine Diseases | 1 | 2009 | 40 | 0.090 |
Why?
|
| Hormone Antagonists | 1 | 2009 | 101 | 0.080 |
Why?
|
| Feasibility Studies | 6 | 2017 | 2292 | 0.080 |
Why?
|
| Colon | 2 | 2010 | 670 | 0.080 |
Why?
|
| Mifepristone | 1 | 2009 | 147 | 0.080 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 280 | 0.080 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2010 | 192 | 0.080 |
Why?
|
| Prognosis | 8 | 2019 | 21713 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2011 | 9244 | 0.080 |
Why?
|
| Medical Illustration | 1 | 2007 | 34 | 0.080 |
Why?
|
| Mass Screening | 3 | 2012 | 1509 | 0.080 |
Why?
|
| Lymphoma | 2 | 2013 | 1467 | 0.080 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 660 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 615 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2013 | 5437 | 0.070 |
Why?
|
| Sarcoma | 1 | 1998 | 1725 | 0.070 |
Why?
|
| Radiography | 4 | 2010 | 1904 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 585 | 0.070 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 14289 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 840 | 0.070 |
Why?
|
| Research | 1 | 2009 | 415 | 0.070 |
Why?
|
| Survival Rate | 4 | 2018 | 12221 | 0.070 |
Why?
|
| Radiography, Abdominal | 1 | 2006 | 120 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 672 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2006 | 699 | 0.060 |
Why?
|
| Neoplasms | 2 | 2010 | 15193 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 621 | 0.060 |
Why?
|
| Radiology | 1 | 2010 | 434 | 0.060 |
Why?
|
| Uterus | 1 | 2009 | 678 | 0.060 |
Why?
|
| Azacitidine | 1 | 2010 | 1149 | 0.060 |
Why?
|
| Kidney Neoplasms | 2 | 2013 | 3022 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 1299 | 0.060 |
Why?
|
| Mesentery | 1 | 2004 | 72 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 918 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 671 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5112 | 0.060 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2004 | 109 | 0.060 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 629 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2006 | 619 | 0.060 |
Why?
|
| Taxoids | 2 | 2020 | 967 | 0.060 |
Why?
|
| False Positive Reactions | 3 | 2010 | 355 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 5178 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 4988 | 0.050 |
Why?
|
| Chemoradiotherapy | 3 | 2020 | 1946 | 0.050 |
Why?
|
| Minerals | 1 | 2022 | 71 | 0.050 |
Why?
|
| Urography | 1 | 2001 | 43 | 0.050 |
Why?
|
| Physical Examination | 2 | 2007 | 299 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 239 | 0.050 |
Why?
|
| Breast Neoplasms | 3 | 2007 | 15694 | 0.050 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 1216 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2009 | 1423 | 0.050 |
Why?
|
| United States | 5 | 2014 | 15433 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 160 | 0.050 |
Why?
|
| Comorbidity | 1 | 2006 | 2352 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2010 | 176 | 0.050 |
Why?
|
| Stromal Cells | 1 | 2004 | 825 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 183 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 226 | 0.040 |
Why?
|
| Mutation | 1 | 2019 | 15179 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2003 | 627 | 0.040 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 1742 | 0.040 |
Why?
|
| Multimodal Imaging | 2 | 2013 | 550 | 0.040 |
Why?
|
| Time Factors | 4 | 2013 | 12926 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 2020 | 152 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 666 | 0.040 |
Why?
|
| Chest Pain | 1 | 2019 | 155 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 11538 | 0.040 |
Why?
|
| Molecular Imaging | 1 | 2019 | 185 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2020 | 241 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2020 | 702 | 0.040 |
Why?
|
| Adolescent | 2 | 2016 | 31252 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2012 | 665 | 0.040 |
Why?
|
| Axilla | 2 | 1997 | 902 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 2017 | 60 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2017 | 145 | 0.040 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2017 | 71 | 0.040 |
Why?
|
| Omentum | 1 | 2017 | 96 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2014 | 9180 | 0.030 |
Why?
|
| Ascites | 1 | 2017 | 198 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2010 | 1014 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 2403 | 0.030 |
Why?
|
| Prevalence | 2 | 2014 | 3260 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2008 | 3890 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2000 | 493 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2008 | 6869 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 231 | 0.030 |
Why?
|
| Age Factors | 2 | 2017 | 5377 | 0.030 |
Why?
|
| Receptors, Progesterone | 2 | 2012 | 1392 | 0.030 |
Why?
|
| Postoperative Care | 2 | 2010 | 739 | 0.030 |
Why?
|
| Lymph Node Excision | 3 | 2014 | 1959 | 0.030 |
Why?
|
| Piperazines | 1 | 2004 | 2101 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 676 | 0.030 |
Why?
|
| Ribs | 1 | 1995 | 91 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 1995 | 128 | 0.030 |
Why?
|
| Abdominal Wall | 1 | 2017 | 184 | 0.030 |
Why?
|
| Disease-Free Survival | 3 | 2012 | 10001 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 5687 | 0.030 |
Why?
|
| Logistic Models | 2 | 2012 | 3441 | 0.030 |
Why?
|
| Neck | 1 | 1996 | 383 | 0.030 |
Why?
|
| Movement | 2 | 2008 | 556 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2006 | 2278 | 0.030 |
Why?
|
| Rectum | 2 | 2005 | 467 | 0.030 |
Why?
|
| Diatrizoate | 1 | 2012 | 12 | 0.030 |
Why?
|
| Iohexol | 1 | 2012 | 58 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1996 | 393 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 2 | 2000 | 5061 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 1154 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2019 | 1230 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 2316 | 0.030 |
Why?
|
| Gastric Lavage | 1 | 2011 | 3 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 2013 | 190 | 0.030 |
Why?
|
| Mammography | 1 | 1997 | 1010 | 0.020 |
Why?
|
| Ileal Neoplasms | 1 | 2011 | 47 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2004 | 3518 | 0.020 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2010 | 8 | 0.020 |
Why?
|
| Bronchial Neoplasms | 1 | 2011 | 79 | 0.020 |
Why?
|
| Pubic Bone | 1 | 2010 | 16 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2803 | 0.020 |
Why?
|
| Acetabulum | 1 | 2010 | 38 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 2010 | 115 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2020 | 2819 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2011 | 355 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4298 | 0.020 |
Why?
|
| Sacrum | 1 | 2010 | 132 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 84 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2330 | 0.020 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2010 | 178 | 0.020 |
Why?
|
| Aorta | 1 | 2013 | 692 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2010 | 272 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 361 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 980 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2010 | 362 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2009 | 342 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 408 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 4975 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1999 | 2326 | 0.020 |
Why?
|
| Musculoskeletal System | 1 | 2006 | 35 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2011 | 492 | 0.020 |
Why?
|
| International Cooperation | 1 | 2007 | 323 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 1555 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 5539 | 0.020 |
Why?
|
| Pancreas | 2 | 2000 | 718 | 0.020 |
Why?
|
| Risk Factors | 3 | 2010 | 17523 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 509 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 1183 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4320 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2007 | 363 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 1144 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 636 | 0.020 |
Why?
|
| Artifacts | 1 | 2007 | 532 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 3472 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 1391 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 2086 | 0.020 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2007 | 356 | 0.020 |
Why?
|
| Child | 2 | 1998 | 29154 | 0.020 |
Why?
|
| Software | 1 | 2011 | 1321 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 2927 | 0.010 |
Why?
|
| Iliac Artery | 1 | 2002 | 108 | 0.010 |
Why?
|
| Radiation Oncology | 1 | 2007 | 529 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 445 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2005 | 575 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2007 | 1987 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 3719 | 0.010 |
Why?
|
| Medical Records | 1 | 2002 | 415 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 698 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 2307 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 6682 | 0.010 |
Why?
|
| Recurrence | 1 | 2009 | 4758 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2010 | 2669 | 0.010 |
Why?
|
| Intestines | 1 | 2005 | 686 | 0.010 |
Why?
|
| Bile Ducts | 1 | 2000 | 113 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 1665 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 1999 | 40 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 3890 | 0.010 |
Why?
|
| Transducers | 1 | 1998 | 59 | 0.010 |
Why?
|
| Spinal Nerve Roots | 1 | 1998 | 65 | 0.010 |
Why?
|
| Benzamides | 1 | 2004 | 1832 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 2002 | 546 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 2203 | 0.010 |
Why?
|
| Dogs | 1 | 1999 | 1155 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 418 | 0.010 |
Why?
|
| Texas | 1 | 2008 | 6311 | 0.010 |
Why?
|
| Feces | 1 | 1999 | 770 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2005 | 2370 | 0.010 |
Why?
|
| Quality of Life | 1 | 2009 | 4532 | 0.010 |
Why?
|
| Swine | 1 | 1999 | 1541 | 0.010 |
Why?
|
| Mastectomy | 1 | 1997 | 1534 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 4849 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1997 | 3005 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 2961 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 16273 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1999 | 7222 | 0.000 |
Why?
|
| Animals | 1 | 1999 | 59536 | 0.000 |
Why?
|